Travera
Keith Ligon is the Chief of Neuropathology at Brigham and Women's Hospital and also holds the position of Associate Pathologist. Keith is a Physician-Researcher and PI at Dana-Farber Cancer Institute, where Keith is the Director of the Center for Patient Derived Models. Additionally, Keith is an Associate Professor at Harvard Medical School and Co-Founder and Scientific Advisor at Travera. Keith Ligon is also an Associate Member at Broad Institute of MIT and Harvard and serves as a Consultant in Pathology at Boston Children's Hospital.
This person is not in any offices
Travera
Travera's initial test is based on this technology; a new measurement tool called the Suspended Microchannel Resonator (SMR) that makes exquisitely precise measurements of the effects of cancer drugs on cancer cells.